News & Events

Goodbye to skin problems with Quest’s Fusid-B

Goodbye to skin problems with Quest’s Fusid-B

Kathmandu, September 5, 2017: 

Skin diseases are among the more widespread of health problems affecting people. Lifestyle and environmental stress aggravate these conditions, causing immense physical as well as mental inconvenience to patients.

Quest Pharmaceuticals has now launched a new drug named ‘Fusid-B’ to help relieve people from dermal infections. The new medication, available as cream, helps treat a wide range of bacterial skin infections like cellulitis, folliculitis, as well as infected dermatitis (also known as eczema).

“Skin diseases are quite prevalent in Nepal. In eight free health camps organized by our team in 2016, we found up to nearly 90% beneficiaries suffering from some sort of skin problems or another,” said S.P.Verma, Director Marketing, Quest Pharmaceuticals P. Ltd.

Fusid-B is a combination of Fusidic Acid and Betamethasone Valerate.

It is available as a prescription drug in top pharmacies across the country.